nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—colon cancer	0.359	1	CiPCiCtD
Capecitabine—TYMS—colon cancer	0.152	1	CbGaD
Capecitabine—breast cancer—colon cancer	0.127	0.537	CtDrD
Capecitabine—stomach cancer—colon cancer	0.109	0.463	CtDrD
Capecitabine—DPYD—Fluorouracil—colon cancer	0.0785	0.395	CbGbCtD
Capecitabine—TYMP—Fluorouracil—colon cancer	0.0522	0.263	CbGbCtD
Capecitabine—TYMS—Fluorouracil—colon cancer	0.0278	0.14	CbGbCtD
Capecitabine—CES1—Irinotecan—colon cancer	0.0226	0.114	CbGbCtD
Capecitabine—TYMS—Methotrexate—colon cancer	0.0153	0.0771	CbGbCtD
Capecitabine—CYP2C9—Fluorouracil—colon cancer	0.0022	0.0111	CbGbCtD
Capecitabine—TYMP—endothelium—colon cancer	0.000986	0.0862	CbGeAlD
Capecitabine—TYMP—blood vessel—colon cancer	0.000909	0.0795	CbGeAlD
Capecitabine—CES1—gall bladder—colon cancer	0.000738	0.0646	CbGeAlD
Capecitabine—DPYD—Pyrimidine metabolism—TYMS—colon cancer	0.00059	0.0614	CbGpPWpGaD
Capecitabine—CDA—lymphoid tissue—colon cancer	0.000566	0.0495	CbGeAlD
Capecitabine—DPYD—bone marrow—colon cancer	0.000535	0.0468	CbGeAlD
Capecitabine—CDA—Pyrimidine metabolism—TYMS—colon cancer	0.000526	0.0547	CbGpPWpGaD
Capecitabine—CDA—bone marrow—colon cancer	0.000515	0.0451	CbGeAlD
Capecitabine—CDA—vagina—colon cancer	0.000494	0.0432	CbGeAlD
Capecitabine—DPYD—Fluoropyrimidine Activity—TYMS—colon cancer	0.000457	0.0476	CbGpPWpGaD
Capecitabine—DPYD—liver—colon cancer	0.000433	0.0379	CbGeAlD
Capecitabine—TYMP—smooth muscle tissue—colon cancer	0.000426	0.0373	CbGeAlD
Capecitabine—TYMP—Pyrimidine metabolism—TYMS—colon cancer	0.00042	0.0437	CbGpPWpGaD
Capecitabine—CDA—liver—colon cancer	0.000416	0.0364	CbGeAlD
Capecitabine—CDA—Fluoropyrimidine Activity—TYMS—colon cancer	0.000408	0.0424	CbGpPWpGaD
Capecitabine—TYMS—smooth muscle tissue—colon cancer	0.000366	0.032	CbGeAlD
Capecitabine—TYMS—Vinorelbine—Vincristine—colon cancer	0.000353	0.593	CbGdCrCtD
Capecitabine—CES1—Irinotecan Pathway—APC—colon cancer	0.00035	0.0364	CbGpPWpGaD
Capecitabine—TYMP—lymphoid tissue—colon cancer	0.000341	0.0298	CbGeAlD
Capecitabine—TYMP—digestive system—colon cancer	0.000337	0.0294	CbGeAlD
Capecitabine—DPYD—lymph node—colon cancer	0.000332	0.029	CbGeAlD
Capecitabine—TYMP—Fluoropyrimidine Activity—TYMS—colon cancer	0.000326	0.0339	CbGpPWpGaD
Capecitabine—CDA—lymph node—colon cancer	0.000319	0.0279	CbGeAlD
Capecitabine—TYMP—bone marrow—colon cancer	0.00031	0.0271	CbGeAlD
Capecitabine—TYMP—vagina—colon cancer	0.000297	0.026	CbGeAlD
Capecitabine—CES1—lymphoid tissue—colon cancer	0.000294	0.0257	CbGeAlD
Capecitabine—TYMS—lymphoid tissue—colon cancer	0.000292	0.0256	CbGeAlD
Capecitabine—CES1—digestive system—colon cancer	0.000291	0.0254	CbGeAlD
Capecitabine—TYMS—digestive system—colon cancer	0.000289	0.0253	CbGeAlD
Capecitabine—TYMP—Bladder Cancer—FGFR3—colon cancer	0.000274	0.0285	CbGpPWpGaD
Capecitabine—TYMS—bone marrow—colon cancer	0.000266	0.0233	CbGeAlD
Capecitabine—TYMS—vagina—colon cancer	0.000255	0.0223	CbGeAlD
Capecitabine—TYMP—liver—colon cancer	0.000251	0.0219	CbGeAlD
Capecitabine—TYMS—Vinblastine—Vincristine—colon cancer	0.000243	0.407	CbGdCrCtD
Capecitabine—CES1—Fluoropyrimidine Activity—TYMS—colon cancer	0.00024	0.025	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—BRAF—colon cancer	0.000236	0.0246	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—CDH1—colon cancer	0.000231	0.0241	CbGpPWpGaD
Capecitabine—DPYD—Nucleotide metabolism—TYMS—colon cancer	0.00023	0.0239	CbGpPWpGaD
Capecitabine—CES1—liver—colon cancer	0.000216	0.0189	CbGeAlD
Capecitabine—TYMS—liver—colon cancer	0.000215	0.0188	CbGeAlD
Capecitabine—CDA—Nucleotide metabolism—TYMS—colon cancer	0.000205	0.0213	CbGpPWpGaD
Capecitabine—TYMP—lymph node—colon cancer	0.000192	0.0168	CbGeAlD
Capecitabine—TYMP—Bladder Cancer—CCND1—colon cancer	0.000173	0.0179	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—CDKN1A—colon cancer	0.000167	0.0174	CbGpPWpGaD
Capecitabine—CES1—lymph node—colon cancer	0.000166	0.0145	CbGeAlD
Capecitabine—TYMS—lymph node—colon cancer	0.000165	0.0144	CbGeAlD
Capecitabine—TYMP—Nucleotide metabolism—TYMS—colon cancer	0.000164	0.017	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.000161	0.0168	CbGpPWpGaD
Capecitabine—DPYD—Fluoropyrimidine Activity—TP53—colon cancer	0.000152	0.0158	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—VEGFA—colon cancer	0.00015	0.0156	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—MYC—colon cancer	0.000138	0.0144	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—EGFR—colon cancer	0.000135	0.0141	CbGpPWpGaD
Capecitabine—CDA—Fluoropyrimidine Activity—TP53—colon cancer	0.000135	0.0141	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CA7—colon cancer	0.000133	0.0138	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—TYMS—colon cancer	0.000127	0.0132	CbGpPWpGaD
Capecitabine—CYP2C9—digestive system—colon cancer	0.000126	0.011	CbGeAlD
Capecitabine—CDA—Metabolism—CA7—colon cancer	0.000118	0.0123	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000116	0.0121	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—TP53—colon cancer	0.000114	0.0118	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—TOP1—colon cancer	0.000112	0.0116	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—HRAS—colon cancer	0.000109	0.0113	CbGpPWpGaD
Capecitabine—TYMP—Fluoropyrimidine Activity—TP53—colon cancer	0.000108	0.0112	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000106	0.011	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CA7—colon cancer	9.46e-05	0.00984	CbGpPWpGaD
Capecitabine—CYP2C9—liver—colon cancer	9.39e-05	0.00822	CbGeAlD
Capecitabine—DPYD—Metabolism—ODC1—colon cancer	8.04e-05	0.00837	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CHST5—colon cancer	8.04e-05	0.00837	CbGpPWpGaD
Capecitabine—CES1—Fluoropyrimidine Activity—TP53—colon cancer	7.97e-05	0.00829	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	7.93e-05	0.00825	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ODC1—colon cancer	7.17e-05	0.00746	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CHST5—colon cancer	7.17e-05	0.00746	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	6.68e-05	0.00695	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—CDKN1A—colon cancer	6.2e-05	0.00645	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—MLH3—colon cancer	6.17e-05	0.00642	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—EP300—colon cancer	5.9e-05	0.00614	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ODC1—colon cancer	5.73e-05	0.00596	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CHST5—colon cancer	5.73e-05	0.00596	CbGpPWpGaD
Capecitabine—TYMS—Fluoropyrimidine Activity—TP53—colon cancer	5.53e-05	0.00575	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	5.34e-05	0.00555	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—MYC—colon cancer	5.14e-05	0.00535	CbGpPWpGaD
Capecitabine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	5.01e-05	0.00522	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	4.87e-05	0.00507	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CA7—colon cancer	4.84e-05	0.00503	CbGpPWpGaD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	4.78e-05	0.00497	CbGpPWpGaD
Capecitabine—Connective tissue disorder—Vincristine—colon cancer	4.6e-05	0.00139	CcSEcCtD
Capecitabine—Urethral disorder—Vincristine—colon cancer	4.59e-05	0.00139	CcSEcCtD
Capecitabine—Epistaxis—Fluorouracil—colon cancer	4.59e-05	0.00139	CcSEcCtD
Capecitabine—Haemoglobin—Irinotecan—colon cancer	4.58e-05	0.00138	CcSEcCtD
Capecitabine—Rhinitis—Irinotecan—colon cancer	4.57e-05	0.00138	CcSEcCtD
Capecitabine—Haemorrhage—Irinotecan—colon cancer	4.56e-05	0.00138	CcSEcCtD
Capecitabine—Agranulocytosis—Fluorouracil—colon cancer	4.54e-05	0.00137	CcSEcCtD
Capecitabine—Pulmonary embolism—Methotrexate—colon cancer	4.52e-05	0.00137	CcSEcCtD
Capecitabine—Connective tissue disorder—Irinotecan—colon cancer	4.48e-05	0.00135	CcSEcCtD
Capecitabine—Melaena—Methotrexate—colon cancer	4.42e-05	0.00133	CcSEcCtD
Capecitabine—Visual impairment—Irinotecan—colon cancer	4.39e-05	0.00133	CcSEcCtD
Capecitabine—Haemoglobin—Fluorouracil—colon cancer	4.39e-05	0.00133	CcSEcCtD
Capecitabine—Rhinitis—Fluorouracil—colon cancer	4.38e-05	0.00132	CcSEcCtD
Capecitabine—Depressed level of consciousness—Methotrexate—colon cancer	4.37e-05	0.00132	CcSEcCtD
Capecitabine—Haemorrhage—Fluorouracil—colon cancer	4.37e-05	0.00132	CcSEcCtD
Capecitabine—Cardiac disorder—Vincristine—colon cancer	4.35e-05	0.00131	CcSEcCtD
Capecitabine—Hypoaesthesia—Fluorouracil—colon cancer	4.35e-05	0.00131	CcSEcCtD
Capecitabine—Pharyngitis—Fluorouracil—colon cancer	4.33e-05	0.00131	CcSEcCtD
Capecitabine—Skin exfoliation—Methotrexate—colon cancer	4.32e-05	0.0013	CcSEcCtD
Capecitabine—TYMS—E2F transcription factor network—CDKN1A—colon cancer	4.3e-05	0.00448	CbGpPWpGaD
Capecitabine—Angiopathy—Vincristine—colon cancer	4.25e-05	0.00128	CcSEcCtD
Capecitabine—Cardiac disorder—Irinotecan—colon cancer	4.23e-05	0.00128	CcSEcCtD
Capecitabine—Flushing—Irinotecan—colon cancer	4.23e-05	0.00128	CcSEcCtD
Capecitabine—Mediastinal disorder—Vincristine—colon cancer	4.22e-05	0.00127	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	4.17e-05	0.00433	CbGpPWpGaD
Capecitabine—Alopecia—Vincristine—colon cancer	4.14e-05	0.00125	CcSEcCtD
Capecitabine—Angiopathy—Irinotecan—colon cancer	4.14e-05	0.00125	CcSEcCtD
Capecitabine—Immune system disorder—Irinotecan—colon cancer	4.12e-05	0.00124	CcSEcCtD
Capecitabine—Mediastinal disorder—Irinotecan—colon cancer	4.11e-05	0.00124	CcSEcCtD
Capecitabine—Mental disorder—Vincristine—colon cancer	4.1e-05	0.00124	CcSEcCtD
Capecitabine—TYMS—E2F transcription factor network—EP300—colon cancer	4.09e-05	0.00426	CbGpPWpGaD
Capecitabine—Chills—Irinotecan—colon cancer	4.09e-05	0.00124	CcSEcCtD
Capecitabine—Ecchymosis—Methotrexate—colon cancer	4.09e-05	0.00124	CcSEcCtD
Capecitabine—Mouth ulceration—Methotrexate—colon cancer	4.09e-05	0.00124	CcSEcCtD
Capecitabine—Neoplasm—Methotrexate—colon cancer	4.09e-05	0.00124	CcSEcCtD
Capecitabine—Urine output increased—Methotrexate—colon cancer	4.09e-05	0.00124	CcSEcCtD
Capecitabine—Arrhythmia—Irinotecan—colon cancer	4.07e-05	0.00123	CcSEcCtD
Capecitabine—Alopecia—Irinotecan—colon cancer	4.03e-05	0.00122	CcSEcCtD
Capecitabine—Back pain—Vincristine—colon cancer	3.94e-05	0.00119	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	3.94e-05	0.0041	CbGpPWpGaD
Capecitabine—Sepsis—Methotrexate—colon cancer	3.93e-05	0.00119	CcSEcCtD
Capecitabine—Flatulence—Irinotecan—colon cancer	3.91e-05	0.00118	CcSEcCtD
Capecitabine—Arrhythmia—Fluorouracil—colon cancer	3.9e-05	0.00118	CcSEcCtD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	3.87e-05	0.00402	CbGpPWpGaD
Capecitabine—Alopecia—Fluorouracil—colon cancer	3.86e-05	0.00117	CcSEcCtD
Capecitabine—Back pain—Irinotecan—colon cancer	3.84e-05	0.00116	CcSEcCtD
Capecitabine—Muscle spasms—Irinotecan—colon cancer	3.82e-05	0.00115	CcSEcCtD
Capecitabine—Erythema—Fluorouracil—colon cancer	3.8e-05	0.00115	CcSEcCtD
Capecitabine—Thrombophlebitis—Methotrexate—colon cancer	3.79e-05	0.00115	CcSEcCtD
Capecitabine—Diabetes mellitus—Methotrexate—colon cancer	3.78e-05	0.00114	CcSEcCtD
Capecitabine—Anaemia—Vincristine—colon cancer	3.77e-05	0.00114	CcSEcCtD
Capecitabine—Photosensitivity—Methotrexate—colon cancer	3.74e-05	0.00113	CcSEcCtD
Capecitabine—Polyuria—Methotrexate—colon cancer	3.74e-05	0.00113	CcSEcCtD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	3.74e-05	0.00389	CbGpPWpGaD
Capecitabine—Ill-defined disorder—Irinotecan—colon cancer	3.68e-05	0.00111	CcSEcCtD
Capecitabine—Anaemia—Irinotecan—colon cancer	3.67e-05	0.00111	CcSEcCtD
Capecitabine—Vertigo—Vincristine—colon cancer	3.66e-05	0.00111	CcSEcCtD
Capecitabine—Hepatic failure—Methotrexate—colon cancer	3.65e-05	0.0011	CcSEcCtD
Capecitabine—Leukopenia—Vincristine—colon cancer	3.65e-05	0.0011	CcSEcCtD
Capecitabine—Vision blurred—Fluorouracil—colon cancer	3.58e-05	0.00108	CcSEcCtD
Capecitabine—Malaise—Irinotecan—colon cancer	3.58e-05	0.00108	CcSEcCtD
Capecitabine—TYMS—E2F transcription factor network—MYC—colon cancer	3.57e-05	0.00371	CbGpPWpGaD
Capecitabine—Vertigo—Irinotecan—colon cancer	3.57e-05	0.00108	CcSEcCtD
Capecitabine—Syncope—Irinotecan—colon cancer	3.56e-05	0.00107	CcSEcCtD
Capecitabine—Renal failure acute—Methotrexate—colon cancer	3.56e-05	0.00107	CcSEcCtD
Capecitabine—Leukopenia—Irinotecan—colon cancer	3.55e-05	0.00107	CcSEcCtD
Capecitabine—Hypertension—Vincristine—colon cancer	3.52e-05	0.00106	CcSEcCtD
Capecitabine—Anaemia—Fluorouracil—colon cancer	3.51e-05	0.00106	CcSEcCtD
Capecitabine—Loss of consciousness—Irinotecan—colon cancer	3.49e-05	0.00105	CcSEcCtD
Capecitabine—Dermatitis exfoliative—Methotrexate—colon cancer	3.48e-05	0.00105	CcSEcCtD
Capecitabine—Myalgia—Vincristine—colon cancer	3.47e-05	0.00105	CcSEcCtD
Capecitabine—Cough—Irinotecan—colon cancer	3.46e-05	0.00105	CcSEcCtD
Capecitabine—Hypertension—Irinotecan—colon cancer	3.43e-05	0.00103	CcSEcCtD
Capecitabine—Leukopenia—Fluorouracil—colon cancer	3.4e-05	0.00103	CcSEcCtD
Capecitabine—Cerebrovascular accident—Methotrexate—colon cancer	3.35e-05	0.00101	CcSEcCtD
Capecitabine—Lethargy—Methotrexate—colon cancer	3.35e-05	0.00101	CcSEcCtD
Capecitabine—Discomfort—Irinotecan—colon cancer	3.34e-05	0.00101	CcSEcCtD
Capecitabine—Oedema—Vincristine—colon cancer	3.33e-05	0.001	CcSEcCtD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	3.32e-05	0.00346	CbGpPWpGaD
Capecitabine—Infection—Vincristine—colon cancer	3.3e-05	0.000998	CcSEcCtD
Capecitabine—Osteoarthritis—Methotrexate—colon cancer	3.28e-05	0.000992	CcSEcCtD
Capecitabine—Confusional state—Irinotecan—colon cancer	3.27e-05	0.000986	CcSEcCtD
Capecitabine—Nervous system disorder—Vincristine—colon cancer	3.26e-05	0.000985	CcSEcCtD
Capecitabine—Thrombocytopenia—Vincristine—colon cancer	3.26e-05	0.000983	CcSEcCtD
Capecitabine—Oedema—Irinotecan—colon cancer	3.24e-05	0.000978	CcSEcCtD
Capecitabine—Myalgia—Fluorouracil—colon cancer	3.24e-05	0.000977	CcSEcCtD
Capecitabine—Chest pain—Fluorouracil—colon cancer	3.24e-05	0.000977	CcSEcCtD
Capecitabine—Infection—Irinotecan—colon cancer	3.22e-05	0.000972	CcSEcCtD
Capecitabine—Hyperhidrosis—Vincristine—colon cancer	3.22e-05	0.000971	CcSEcCtD
Capecitabine—Discomfort—Fluorouracil—colon cancer	3.2e-05	0.000966	CcSEcCtD
Capecitabine—Shock—Irinotecan—colon cancer	3.19e-05	0.000962	CcSEcCtD
Capecitabine—Nervous system disorder—Irinotecan—colon cancer	3.18e-05	0.000959	CcSEcCtD
Capecitabine—Thrombocytopenia—Irinotecan—colon cancer	3.17e-05	0.000958	CcSEcCtD
Capecitabine—Anorexia—Vincristine—colon cancer	3.17e-05	0.000957	CcSEcCtD
Capecitabine—Irritability—Methotrexate—colon cancer	3.13e-05	0.000946	CcSEcCtD
Capecitabine—Hyperhidrosis—Irinotecan—colon cancer	3.13e-05	0.000946	CcSEcCtD
Capecitabine—Confusional state—Fluorouracil—colon cancer	3.13e-05	0.000945	CcSEcCtD
Capecitabine—TYMS—G1/S Transition—CDKN1A—colon cancer	3.12e-05	0.00325	CbGpPWpGaD
Capecitabine—Mood swings—Methotrexate—colon cancer	3.11e-05	0.000939	CcSEcCtD
Capecitabine—Hypotension—Vincristine—colon cancer	3.11e-05	0.000939	CcSEcCtD
Capecitabine—Oedema—Fluorouracil—colon cancer	3.1e-05	0.000937	CcSEcCtD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—MYC—colon cancer	3.1e-05	0.00323	CbGpPWpGaD
Capecitabine—Anorexia—Irinotecan—colon cancer	3.09e-05	0.000932	CcSEcCtD
Capecitabine—Ataxia—Methotrexate—colon cancer	3.09e-05	0.000932	CcSEcCtD
Capecitabine—Infection—Fluorouracil—colon cancer	3.08e-05	0.000931	CcSEcCtD
Capecitabine—Nervous system disorder—Fluorouracil—colon cancer	3.04e-05	0.000919	CcSEcCtD
Capecitabine—Thrombocytopenia—Fluorouracil—colon cancer	3.04e-05	0.000917	CcSEcCtD
Capecitabine—Liver function test abnormal—Methotrexate—colon cancer	3.03e-05	0.000915	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Vincristine—colon cancer	3.03e-05	0.000915	CcSEcCtD
Capecitabine—Tachycardia—Fluorouracil—colon cancer	3.03e-05	0.000914	CcSEcCtD
Capecitabine—Hypotension—Irinotecan—colon cancer	3.03e-05	0.000914	CcSEcCtD
Capecitabine—Insomnia—Vincristine—colon cancer	3.01e-05	0.000908	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3e-05	0.00312	CbGpPWpGaD
Capecitabine—Paraesthesia—Vincristine—colon cancer	2.99e-05	0.000902	CcSEcCtD
Capecitabine—Breast disorder—Methotrexate—colon cancer	2.97e-05	0.000896	CcSEcCtD
Capecitabine—Anorexia—Fluorouracil—colon cancer	2.96e-05	0.000893	CcSEcCtD
Capecitabine—Toxic epidermal necrolysis—Methotrexate—colon cancer	2.96e-05	0.000893	CcSEcCtD
Capecitabine—CES1—NRF2 pathway—TGFB1—colon cancer	2.95e-05	0.00306	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CHST5—colon cancer	2.93e-05	0.00305	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ODC1—colon cancer	2.93e-05	0.00305	CbGpPWpGaD
Capecitabine—Insomnia—Irinotecan—colon cancer	2.93e-05	0.000885	CcSEcCtD
Capecitabine—Paraesthesia—Irinotecan—colon cancer	2.91e-05	0.000878	CcSEcCtD
Capecitabine—Hypotension—Fluorouracil—colon cancer	2.9e-05	0.000875	CcSEcCtD
Capecitabine—Decreased appetite—Vincristine—colon cancer	2.89e-05	0.000873	CcSEcCtD
Capecitabine—Dyspnoea—Irinotecan—colon cancer	2.89e-05	0.000872	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Vincristine—colon cancer	2.87e-05	0.000867	CcSEcCtD
Capecitabine—Fatigue—Vincristine—colon cancer	2.87e-05	0.000866	CcSEcCtD
Capecitabine—Dyspepsia—Irinotecan—colon cancer	2.85e-05	0.000861	CcSEcCtD
Capecitabine—Pain—Vincristine—colon cancer	2.84e-05	0.000859	CcSEcCtD
Capecitabine—Constipation—Vincristine—colon cancer	2.84e-05	0.000859	CcSEcCtD
Capecitabine—Asthma—Methotrexate—colon cancer	2.84e-05	0.000857	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Fluorouracil—colon cancer	2.83e-05	0.000854	CcSEcCtD
Capecitabine—Decreased appetite—Irinotecan—colon cancer	2.82e-05	0.00085	CcSEcCtD
Capecitabine—Insomnia—Fluorouracil—colon cancer	2.81e-05	0.000847	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Irinotecan—colon cancer	2.8e-05	0.000844	CcSEcCtD
Capecitabine—Fatigue—Irinotecan—colon cancer	2.79e-05	0.000843	CcSEcCtD
Capecitabine—Paraesthesia—Fluorouracil—colon cancer	2.79e-05	0.000841	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—PPARG—colon cancer	2.78e-05	0.00289	CbGpPWpGaD
Capecitabine—Constipation—Irinotecan—colon cancer	2.77e-05	0.000836	CcSEcCtD
Capecitabine—Pain—Irinotecan—colon cancer	2.77e-05	0.000836	CcSEcCtD
Capecitabine—Dyspnoea—Fluorouracil—colon cancer	2.77e-05	0.000835	CcSEcCtD
Capecitabine—Dyspepsia—Fluorouracil—colon cancer	2.73e-05	0.000825	CcSEcCtD
Capecitabine—Abdominal discomfort—Methotrexate—colon cancer	2.72e-05	0.000822	CcSEcCtD
Capecitabine—Gastrointestinal pain—Vincristine—colon cancer	2.72e-05	0.000821	CcSEcCtD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CCND1—colon cancer	2.72e-05	0.00283	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—MLH1—colon cancer	2.72e-05	0.00283	CbGpPWpGaD
Capecitabine—Decreased appetite—Fluorouracil—colon cancer	2.7e-05	0.000814	CcSEcCtD
Capecitabine—Pancytopenia—Methotrexate—colon cancer	2.7e-05	0.000814	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Fluorouracil—colon cancer	2.68e-05	0.000809	CcSEcCtD
Capecitabine—Feeling abnormal—Irinotecan—colon cancer	2.67e-05	0.000806	CcSEcCtD
Capecitabine—Neutropenia—Methotrexate—colon cancer	2.65e-05	0.000801	CcSEcCtD
Capecitabine—Dysuria—Methotrexate—colon cancer	2.65e-05	0.000801	CcSEcCtD
Capecitabine—Pain—Fluorouracil—colon cancer	2.65e-05	0.000801	CcSEcCtD
Capecitabine—Gastrointestinal pain—Irinotecan—colon cancer	2.65e-05	0.0008	CcSEcCtD
Capecitabine—Upper respiratory tract infection—Methotrexate—colon cancer	2.64e-05	0.000796	CcSEcCtD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDKN1A—colon cancer	2.63e-05	0.00274	CbGpPWpGaD
Capecitabine—Abdominal pain—Vincristine—colon cancer	2.63e-05	0.000794	CcSEcCtD
Capecitabine—Body temperature increased—Vincristine—colon cancer	2.63e-05	0.000794	CcSEcCtD
Capecitabine—Photosensitivity reaction—Methotrexate—colon cancer	2.59e-05	0.000782	CcSEcCtD
Capecitabine—TYMS—G1/S Transition—MYC—colon cancer	2.59e-05	0.00269	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—BUB1B—colon cancer	2.58e-05	0.00269	CbGpPWpGaD
Capecitabine—Abdominal pain—Irinotecan—colon cancer	2.56e-05	0.000773	CcSEcCtD
Capecitabine—Body temperature increased—Irinotecan—colon cancer	2.56e-05	0.000773	CcSEcCtD
Capecitabine—Feeling abnormal—Fluorouracil—colon cancer	2.56e-05	0.000772	CcSEcCtD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—colon cancer	2.55e-05	0.00265	CbGpPWpGaD
Capecitabine—Pneumonia—Methotrexate—colon cancer	2.55e-05	0.000769	CcSEcCtD
Capecitabine—Infestation NOS—Methotrexate—colon cancer	2.53e-05	0.000764	CcSEcCtD
Capecitabine—Infestation—Methotrexate—colon cancer	2.53e-05	0.000764	CcSEcCtD
Capecitabine—Depression—Methotrexate—colon cancer	2.52e-05	0.000762	CcSEcCtD
Capecitabine—Stevens-Johnson syndrome—Methotrexate—colon cancer	2.51e-05	0.000758	CcSEcCtD
Capecitabine—Renal failure—Methotrexate—colon cancer	2.49e-05	0.000751	CcSEcCtD
Capecitabine—Stomatitis—Methotrexate—colon cancer	2.47e-05	0.000745	CcSEcCtD
Capecitabine—Urticaria—Fluorouracil—colon cancer	2.46e-05	0.000744	CcSEcCtD
Capecitabine—Conjunctivitis—Methotrexate—colon cancer	2.46e-05	0.000743	CcSEcCtD
Capecitabine—Body temperature increased—Fluorouracil—colon cancer	2.45e-05	0.000741	CcSEcCtD
Capecitabine—Hypersensitivity—Vincristine—colon cancer	2.45e-05	0.00074	CcSEcCtD
Capecitabine—Haematuria—Methotrexate—colon cancer	2.41e-05	0.000729	CcSEcCtD
Capecitabine—Hepatobiliary disease—Methotrexate—colon cancer	2.39e-05	0.000723	CcSEcCtD
Capecitabine—Epistaxis—Methotrexate—colon cancer	2.39e-05	0.000721	CcSEcCtD
Capecitabine—Hypersensitivity—Irinotecan—colon cancer	2.39e-05	0.000721	CcSEcCtD
Capecitabine—Asthenia—Vincristine—colon cancer	2.39e-05	0.000721	CcSEcCtD
Capecitabine—Agranulocytosis—Methotrexate—colon cancer	2.36e-05	0.000713	CcSEcCtD
Capecitabine—Asthenia—Irinotecan—colon cancer	2.32e-05	0.000702	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—BUB1B—colon cancer	2.31e-05	0.0024	CbGpPWpGaD
Capecitabine—Hypersensitivity—Fluorouracil—colon cancer	2.29e-05	0.00069	CcSEcCtD
Capecitabine—Haemoglobin—Methotrexate—colon cancer	2.28e-05	0.000689	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.28e-05	0.00237	CbGpPWpGaD
Capecitabine—Diarrhoea—Vincristine—colon cancer	2.28e-05	0.000687	CcSEcCtD
Capecitabine—Hepatitis—Methotrexate—colon cancer	2.27e-05	0.000686	CcSEcCtD
Capecitabine—Haemorrhage—Methotrexate—colon cancer	2.27e-05	0.000686	CcSEcCtD
Capecitabine—Pharyngitis—Methotrexate—colon cancer	2.25e-05	0.000681	CcSEcCtD
Capecitabine—Urinary tract disorder—Methotrexate—colon cancer	2.24e-05	0.000677	CcSEcCtD
Capecitabine—Urethral disorder—Methotrexate—colon cancer	2.23e-05	0.000672	CcSEcCtD
Capecitabine—Diarrhoea—Irinotecan—colon cancer	2.22e-05	0.000669	CcSEcCtD
Capecitabine—Dizziness—Vincristine—colon cancer	2.2e-05	0.000664	CcSEcCtD
Capecitabine—Pruritus—Fluorouracil—colon cancer	2.2e-05	0.000663	CcSEcCtD
Capecitabine—Visual impairment—Methotrexate—colon cancer	2.19e-05	0.000661	CcSEcCtD
Capecitabine—TYMS—Mitotic G1-G1/S phases—MYC—colon cancer	2.18e-05	0.00227	CbGpPWpGaD
Capecitabine—Erythema multiforme—Methotrexate—colon cancer	2.15e-05	0.000649	CcSEcCtD
Capecitabine—Dizziness—Irinotecan—colon cancer	2.14e-05	0.000647	CcSEcCtD
Capecitabine—DPYD—Metabolism—ABCB1—colon cancer	2.13e-05	0.00221	CbGpPWpGaD
Capecitabine—Eye disorder—Methotrexate—colon cancer	2.12e-05	0.000641	CcSEcCtD
Capecitabine—Diarrhoea—Fluorouracil—colon cancer	2.12e-05	0.000641	CcSEcCtD
Capecitabine—Tinnitus—Methotrexate—colon cancer	2.12e-05	0.00064	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.12e-05	0.0022	CbGpPWpGaD
Capecitabine—Vomiting—Vincristine—colon cancer	2.11e-05	0.000639	CcSEcCtD
Capecitabine—Cardiac disorder—Methotrexate—colon cancer	2.11e-05	0.000637	CcSEcCtD
Capecitabine—Rash—Vincristine—colon cancer	2.1e-05	0.000633	CcSEcCtD
Capecitabine—Dermatitis—Vincristine—colon cancer	2.1e-05	0.000633	CcSEcCtD
Capecitabine—DPYD—Metabolism—TYMS—colon cancer	2.09e-05	0.00217	CbGpPWpGaD
Capecitabine—Headache—Vincristine—colon cancer	2.08e-05	0.000629	CcSEcCtD
Capecitabine—Angiopathy—Methotrexate—colon cancer	2.06e-05	0.000622	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.06e-05	0.00214	CbGpPWpGaD
Capecitabine—Vomiting—Irinotecan—colon cancer	2.06e-05	0.000622	CcSEcCtD
Capecitabine—Immune system disorder—Methotrexate—colon cancer	2.05e-05	0.00062	CcSEcCtD
Capecitabine—Dizziness—Fluorouracil—colon cancer	2.05e-05	0.00062	CcSEcCtD
Capecitabine—Mediastinal disorder—Methotrexate—colon cancer	2.05e-05	0.000618	CcSEcCtD
Capecitabine—Rash—Irinotecan—colon cancer	2.04e-05	0.000617	CcSEcCtD
Capecitabine—Dermatitis—Irinotecan—colon cancer	2.04e-05	0.000616	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.04e-05	0.00212	CbGpPWpGaD
Capecitabine—Chills—Methotrexate—colon cancer	2.04e-05	0.000615	CcSEcCtD
Capecitabine—Headache—Irinotecan—colon cancer	2.03e-05	0.000613	CcSEcCtD
Capecitabine—Alopecia—Methotrexate—colon cancer	2.01e-05	0.000606	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.99e-05	0.00207	CbGpPWpGaD
Capecitabine—Mental disorder—Methotrexate—colon cancer	1.99e-05	0.000601	CcSEcCtD
Capecitabine—Malnutrition—Methotrexate—colon cancer	1.98e-05	0.000597	CcSEcCtD
Capecitabine—Erythema—Methotrexate—colon cancer	1.98e-05	0.000597	CcSEcCtD
Capecitabine—Nausea—Vincristine—colon cancer	1.98e-05	0.000597	CcSEcCtD
Capecitabine—Vomiting—Fluorouracil—colon cancer	1.97e-05	0.000596	CcSEcCtD
Capecitabine—Rash—Fluorouracil—colon cancer	1.96e-05	0.000591	CcSEcCtD
Capecitabine—Dermatitis—Fluorouracil—colon cancer	1.95e-05	0.00059	CcSEcCtD
Capecitabine—Headache—Fluorouracil—colon cancer	1.94e-05	0.000587	CcSEcCtD
Capecitabine—Dysgeusia—Methotrexate—colon cancer	1.94e-05	0.000585	CcSEcCtD
Capecitabine—Nausea—Irinotecan—colon cancer	1.92e-05	0.000581	CcSEcCtD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	1.92e-05	0.002	CbGpPWpGaD
Capecitabine—Back pain—Methotrexate—colon cancer	1.91e-05	0.000578	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.9e-05	0.00197	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ABCB1—colon cancer	1.89e-05	0.00197	CbGpPWpGaD
Capecitabine—Vision blurred—Methotrexate—colon cancer	1.86e-05	0.000563	CcSEcCtD
Capecitabine—CDA—Metabolism—TYMS—colon cancer	1.86e-05	0.00194	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.84e-05	0.00192	CbGpPWpGaD
Capecitabine—Nausea—Fluorouracil—colon cancer	1.84e-05	0.000556	CcSEcCtD
Capecitabine—Ill-defined disorder—Methotrexate—colon cancer	1.83e-05	0.000554	CcSEcCtD
Capecitabine—Anaemia—Methotrexate—colon cancer	1.83e-05	0.000552	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—EP300—colon cancer	1.82e-05	0.00189	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.8e-05	0.00187	CbGpPWpGaD
Capecitabine—Malaise—Methotrexate—colon cancer	1.78e-05	0.000538	CcSEcCtD
Capecitabine—Vertigo—Methotrexate—colon cancer	1.78e-05	0.000536	CcSEcCtD
Capecitabine—Leukopenia—Methotrexate—colon cancer	1.77e-05	0.000535	CcSEcCtD
Capecitabine—Cough—Methotrexate—colon cancer	1.73e-05	0.000521	CcSEcCtD
Capecitabine—Arthralgia—Methotrexate—colon cancer	1.68e-05	0.000508	CcSEcCtD
Capecitabine—Chest pain—Methotrexate—colon cancer	1.68e-05	0.000508	CcSEcCtD
Capecitabine—Myalgia—Methotrexate—colon cancer	1.68e-05	0.000508	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	1.67e-05	0.000505	CcSEcCtD
Capecitabine—Discomfort—Methotrexate—colon cancer	1.66e-05	0.000502	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.65e-05	0.00172	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.65e-05	0.00172	CbGpPWpGaD
Capecitabine—Confusional state—Methotrexate—colon cancer	1.63e-05	0.000491	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.62e-05	0.00168	CbGpPWpGaD
Capecitabine—Infection—Methotrexate—colon cancer	1.6e-05	0.000484	CcSEcCtD
Capecitabine—Nervous system disorder—Methotrexate—colon cancer	1.58e-05	0.000478	CcSEcCtD
Capecitabine—Thrombocytopenia—Methotrexate—colon cancer	1.58e-05	0.000477	CcSEcCtD
Capecitabine—Skin disorder—Methotrexate—colon cancer	1.57e-05	0.000473	CcSEcCtD
Capecitabine—Hyperhidrosis—Methotrexate—colon cancer	1.56e-05	0.000471	CcSEcCtD
Capecitabine—Anorexia—Methotrexate—colon cancer	1.54e-05	0.000465	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.53e-05	0.00159	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ABCB1—colon cancer	1.51e-05	0.00158	CbGpPWpGaD
Capecitabine—Hypotension—Methotrexate—colon cancer	1.51e-05	0.000455	CcSEcCtD
Capecitabine—TYMP—Metabolism—TYMS—colon cancer	1.49e-05	0.00155	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PPARG—colon cancer	1.48e-05	0.00154	CbGpPWpGaD
Capecitabine—Musculoskeletal discomfort—Methotrexate—colon cancer	1.47e-05	0.000444	CcSEcCtD
Capecitabine—Insomnia—Methotrexate—colon cancer	1.46e-05	0.000441	CcSEcCtD
Capecitabine—Paraesthesia—Methotrexate—colon cancer	1.45e-05	0.000438	CcSEcCtD
Capecitabine—Dyspnoea—Methotrexate—colon cancer	1.44e-05	0.000434	CcSEcCtD
Capecitabine—Dyspepsia—Methotrexate—colon cancer	1.42e-05	0.000429	CcSEcCtD
Capecitabine—Decreased appetite—Methotrexate—colon cancer	1.4e-05	0.000424	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.4e-05	0.00146	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CA7—colon cancer	1.4e-05	0.00145	CbGpPWpGaD
Capecitabine—Gastrointestinal disorder—Methotrexate—colon cancer	1.39e-05	0.000421	CcSEcCtD
Capecitabine—Fatigue—Methotrexate—colon cancer	1.39e-05	0.00042	CcSEcCtD
Capecitabine—Pain—Methotrexate—colon cancer	1.38e-05	0.000417	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.36e-05	0.00141	CbGpPWpGaD
Capecitabine—Feeling abnormal—Methotrexate—colon cancer	1.33e-05	0.000402	CcSEcCtD
Capecitabine—Gastrointestinal pain—Methotrexate—colon cancer	1.32e-05	0.000399	CcSEcCtD
Capecitabine—CDA—Metabolism—PPARG—colon cancer	1.32e-05	0.00137	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—TP53—colon cancer	1.3e-05	0.00136	CbGpPWpGaD
Capecitabine—Urticaria—Methotrexate—colon cancer	1.28e-05	0.000387	CcSEcCtD
Capecitabine—Body temperature increased—Methotrexate—colon cancer	1.28e-05	0.000385	CcSEcCtD
Capecitabine—Abdominal pain—Methotrexate—colon cancer	1.28e-05	0.000385	CcSEcCtD
Capecitabine—Hypersensitivity—Methotrexate—colon cancer	1.19e-05	0.000359	CcSEcCtD
Capecitabine—DPYD—Metabolism—PTGS2—colon cancer	1.16e-05	0.00121	CbGpPWpGaD
Capecitabine—Asthenia—Methotrexate—colon cancer	1.16e-05	0.00035	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.15e-05	0.00119	CbGpPWpGaD
Capecitabine—Pruritus—Methotrexate—colon cancer	1.14e-05	0.000345	CcSEcCtD
Capecitabine—Diarrhoea—Methotrexate—colon cancer	1.1e-05	0.000333	CcSEcCtD
Capecitabine—Dizziness—Methotrexate—colon cancer	1.07e-05	0.000322	CcSEcCtD
Capecitabine—TYMP—Metabolism—PPARG—colon cancer	1.05e-05	0.0011	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PTGS2—colon cancer	1.04e-05	0.00108	CbGpPWpGaD
Capecitabine—Vomiting—Methotrexate—colon cancer	1.03e-05	0.00031	CcSEcCtD
Capecitabine—Rash—Methotrexate—colon cancer	1.02e-05	0.000307	CcSEcCtD
Capecitabine—Dermatitis—Methotrexate—colon cancer	1.02e-05	0.000307	CcSEcCtD
Capecitabine—Headache—Methotrexate—colon cancer	1.01e-05	0.000305	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—CCND1—colon cancer	9.97e-06	0.00104	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—EP300—colon cancer	9.68e-06	0.00101	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN1A—colon cancer	9.65e-06	0.001	CbGpPWpGaD
Capecitabine—Nausea—Methotrexate—colon cancer	9.59e-06	0.000289	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—EP300—colon cancer	9.18e-06	0.000955	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CCND1—colon cancer	8.92e-06	0.000928	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CDKN1A—colon cancer	8.63e-06	0.000898	CbGpPWpGaD
Capecitabine—CDA—Metabolism—EP300—colon cancer	8.62e-06	0.000897	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ODC1—colon cancer	8.45e-06	0.000879	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CHST5—colon cancer	8.45e-06	0.000879	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTGS2—colon cancer	8.29e-06	0.000862	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—EP300—colon cancer	8.21e-06	0.000854	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—MYC—colon cancer	8e-06	0.000832	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ABCB1—colon cancer	7.75e-06	0.000806	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PIK3CA—colon cancer	7.16e-06	0.000745	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—MYC—colon cancer	7.15e-06	0.000744	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—EP300—colon cancer	6.89e-06	0.000717	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PIK3CA—colon cancer	6.38e-06	0.000664	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TP53—colon cancer	5.87e-06	0.000611	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—AKT1—colon cancer	5.85e-06	0.000608	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PPARG—colon cancer	5.39e-06	0.000561	CbGpPWpGaD
Capecitabine—CDA—Metabolism—AKT1—colon cancer	5.21e-06	0.000542	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PIK3CA—colon cancer	5.1e-06	0.000531	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS2—colon cancer	4.24e-06	0.000441	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—AKT1—colon cancer	4.17e-06	0.000433	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—EP300—colon cancer	3.53e-06	0.000367	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.49e-06	0.000363	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.74e-06	0.000286	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PIK3CA—colon cancer	2.61e-06	0.000271	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.28e-06	0.000237	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ABCB1—colon cancer	2.23e-06	0.000232	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TYMS—colon cancer	2.19e-06	0.000228	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—AKT1—colon cancer	2.13e-06	0.000222	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.69e-06	0.000176	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PPARG—colon cancer	1.55e-06	0.000162	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS2—colon cancer	1.22e-06	0.000127	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—EP300—colon cancer	1.02e-06	0.000106	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PIK3CA—colon cancer	7.52e-07	7.82e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—AKT1—colon cancer	6.14e-07	6.39e-05	CbGpPWpGaD
